Introduction {#s0005}
============

Breast cancer is the most frequently diagnosed malignancy and the leading cause of cancer death among women worldwide [@bb0005]. However, breast cancer is rare in young women, and approximately 7% of all breast cancers are diagnosed in women under 40 years of age [@bb0010]. The incidence of breast cancer in women younger than 40 years has been stable for the past 20 years in most countries [@bb0015]. Some studies have demonstrated that breast cancer in younger women is correlated with a more aggressive biology and poorer outcomes than breast cancer in older women [@bb0020], [@bb0025], [@bb0030], [@bb0035]. Young women have relatively high proportions of estrogen receptor (ER)--negative and progesterone receptor (PR)--negative cancers, human epidermal growth factor 2 (HER2)--positive cancers, and high-grade cancers [@bb0040], [@bb0045]. They are also more likely to be associated with a positive family history and TP53-positive tumors [@bb0050], [@bb0055].

The benefit of chemotherapy in treating breast cancer in women younger than 50 years has been confirmed [@bb0060]. However, the answers to many questions remain unknown regarding the selection of therapeutic measures for young women with breast cancer, including whether all young women with breast cancer should receive chemotherapy and whether they are candidates for breast-conserving surgery. Therefore, it is important to divide patients into different risk subgroups that receive certain treatments.

Nomograms have been widely used to estimate a numeric probability of death or recurrence in each patient by combining important prognostic factors [@bb0065], [@bb0070], [@bb0075]. To the best of our knowledge, nomograms for predicting overall survival (OS) and breast cancer--specific survival (BCSS) of young women with breast cancer have not been reported. In this study, we aimed to construct comprehensive and practical nomograms for young women with breast cancer based on a large population from the Surveillance, Epidemiology, and End Results (SEER) database. In addition, we compared our nomograms with traditional TNM staging systems to determine their predictive preciseness.

Material and Methods {#s0010}
====================

Study Population {#s0015}
----------------

Data for this study were obtained from the current SEER database, which consists of 18 population-based cancer registries. This database represents approximately 28% of the total population in the United States. SEER\*Stat Version 8.3.4 (http://www.seer.cancer.gov/seerstat) from the National Cancer Institute was used to identify eligible patients [@bb0080].

We included female patients, aged 18 to 39 years, who had been diagnosed with breast cancer as a first primary malignancy between 1990 and 2010. Patients diagnosed before 1990 were not included because ER and PR status was not recorded in the SEER database until 1990. Additionally, to ensure adequate follow-up time, patients diagnosed after 2010 were not included. Only histologically confirmed unilateral breast cancer cases were included. Cases diagnosed at autopsy or by death certificate only were excluded. All variables included in the analysis have less than 10% missing values. Other exclusion criteria for this study included patients with unknown race information, unknown specific surgical treatment including mastectomy and breast-conserving surgery, unknown histological grade or grade IV disease, unknown tumor size and number of positive lymph nodes, stage IV breast cancer, unknown ER and PR status, diagnosis with inflammatory breast cancer and Paget\'s disease, and incomplete survival data. After the exclusion criteria were applied, a total of 24,889 women were eventually eligible for analysis. The flow chart for data selection is shown in [Supplementary Figure 1](#f0020){ref-type="graphic"}.

Construction of the Nomograms {#s0020}
-----------------------------

To establish and validate competing-risks nomograms, the eligible patients were randomly divided into a training (*n* = 12,465) cohort and a validation (*n* = 12,424) cohort.

Race/ethnicity in SEER database was classified into four major groups, including white, black, Asian or Pacific Islander, and American Indian/Alaska Native. Given the small number of American Indian/Alaska Native patients, we incorporate these patients with Asian or Pacific Islander patients into "others" group. Thus, we classified race/ethnicity into three mutually exclusive groups of 1) white, 2) black, and 3) others.

The median follow-up was estimated as the median observed survival time. OS was calculated from the date of diagnosis to the date of death due to any cause, the date of last follow-up, or December 31, 2014. In the training cohort, univariate prognostic factors were determined using the Kaplan-Meier plots and compared using the log-rank tests. Variables that achieved significance at *P* \< .05 were entered into the multivariable analysis via the Cox proportional-hazards model. The independent prognostic factors determined by the multivariate analysis were used to construct a nomogram for OS.

BCSS was measured as the time from the date of diagnosis to the date of death attributed to breast cancer, date of last follow-up, or December 31, 2014. Deaths from other causes were considered competing risks. We used the cumulative incidence function (CIF) to assess the probability of death. Gray\'s test was conducted to test the difference in CIF among groups [@bb0085]. A subdistribution analysis of competing risks was performed to construct a competing-risks model [@bb0090]. In the Cox regression model analyzing disease-specific regression, patients who died from other causes were considered as censored at the data of last follow-up. Thus, a nomogram was developed by the integration of associated risk factors to predict 5- and 10-year BCSS of young patients with breast cancer.

Validation and Calibration of the Nomograms {#s0025}
-------------------------------------------

The nomograms were subjected to 1000 bootstrap resamples for internal validation of the training cohort and external validation with the validation cohort. The concordance index (C-index) between the predicted probability and response was used to assess the discrimination performance of the nomograms [@bb0095]. The value of the C-index ranges from 0.5 to 1.0, with 0.5 indicating a random chance and 1.0 indicating a perfectly corrected discrimination. Comparison of the C-index of two different models was based on previously described methods [@bb0100]. Calibration is the ability of a model to make unbiased estimates of outcome. Marginal estimate versus average predictive probability of the models was used to construct calibration curves. The predictions were expected to fall on a 45° diagonal line in a well-calibrated model.

Risk Group Stratification Based on the Nomogram beyond TNM Staging {#s0030}
------------------------------------------------------------------

In addition to numerically comparing the discrimination ability based on the C-index, we sought to illustrate the independent discrimination ability of the nomogram for OS beyond standard TNM staging. To this end, we determined cutoff values by evenly dividing patients in the training cohort into different risk groups within a certain TNM category according to the total risk scores (from highest to lowest) from the nomogram for OS prediction. These values were then applied to the validation cohort, and the respective Kaplan-Meier survival curves were delineated.

Statistical Analysis {#s0035}
--------------------

All statistical analyses were performed using R software, version 3.4.0 (http://www.r-project.org) and SPSS software, version 22.0 (SPSS, Chicago, IL). The R packages cmprsk [@bb0105] and rms [@bb0110] were used for modeling and developing the nomograms. Two-sided *P* values less than .05 were considered statistically significant.

Results {#s0040}
=======

Patient Characteristics {#s0045}
-----------------------

The entire cohort comprised 24,889 young women with histologically confirmed malignant breast cancer, with 12,465 patients in the training cohort and 12,424 patients in the validation cohort. The demographic and clinical characteristics of the study cohort are shown in [Table 1](#t0005){ref-type="table"}. The majority of tumors were infiltrating ductal carcinoma (84.1%), and most of the patients were non-Hispanic whites (73.1%). The median survival time was 99 months (interquartile range, 63-149 months). By the end of the last follow-up, 5501 patients (22.1%) had died, including 4897 patients (19.7%) who died from breast cancer and 604 patients (2.4%) who died from other causes.Table 1Demographic and Clinical Characteristics of the Study CohortTable 1Demographic and Clinical CharacteristicAll PatientsTraining CohortValidation Cohort*N* = 24,889*N* = 12,465*N* = 12,424Year of diagnosis 1990-19963294 (13.2%)1676 (13.4%)1618 (13.0%) 1997-20038270 (33.3%)4197 (33.7%)4073 (32.8%) 2004-201013,325 (53.5%)6592 (52.9%)6733 (54.2%)Race White18,202 (73.1%)9128 (73.2%)9074 (73.0%) Black3695 (14.9%)1853 (14.9%)1842 (14.9%) Others[\*](#tf0005){ref-type="table-fn"}2992 (12.0%)1484 (11.9%)1508 (12.1%)Laterality Left12,378 (49.7%)6203 (49.8%)6175 (49.7%) Right12,511 (50.3%)6262 (50.2%)6249 (50.3%)Histology IDC20,935 (84.1%)10,511 (84.3%)10,424 (83.9%) ILC1805 (7.3%)903 (7.2%)902 (7.3%) Others[†](#tf0010){ref-type="table-fn"}2149 (8.6%)1051 (8.4%)1098 (8.8%)Grade I1866 (7.5%)905 (7.3%)961 (7.7%) II8288 (33.3%)4178 (33.5%)4110 (33.1%) III14,735 (59.2%)7382 (59.2%)7353 (59.2%)Tumor size (cm) ≤211,833 (47.5%)5970 (47.9%)5863 (47.2%) 2-510,577 (42.5%)5275 (42.3%)5302 (42.7%) \> 52479 (10.0%)1220 (9.8%)1259 (10.1%)No. of positive LNs 012,824 (51.5%)6400 (51.3%)6424 (51.7%) 1-37796 (31.3%)3922 (31.5%)3874 (31.2%) 4-92875 (11.6%)1449 (11.6%)1426 (11.5%) ≥ 101394 (5.6%)694 (5.6%)700 (5.6%)ER status Positive15,746 (63.3%)7858 (63.0%)7888 (63.5%) Negative9143 (36.7%)4607 (37.0%)4536 (36.5%)PR status Positive14,215 (57.1%)7161 (57.4%)7054 (56.8%) Negative10,674 (42.9%)5304 (42.6%)5370 (43.2%)Surgery BCS11,119 (44.7%)5500 (44.1%)5619 (45.2%) Mastectomy13,770 (55.3%)6965 (55.9%)6805 (54.8%)Survival months Median (IQR)99 (63-149)99 (63-150)99 (63-148)[^2][^3][^4]

Overall Survival {#s0050}
----------------

The results of the univariate and multivariate analyses are listed in [Table 2](#t0010){ref-type="table"}. All variables except for laterality of breast cancer were significantly correlated with OS (*P* \< .001 for all). The significant factors in the univariate analysis were subjected to a multivariate analysis based on a Cox proportional-hazards regression model. Race, histology, tumor grade, tumor size, number of positive lymph nodes, ER status, and surgery type were confirmed to be independently associated with OS (*P* \< .05 for all).Table 2Univariate and Multivariate Analysis of OS in the Training CohortTable 2Univariate AnalysisMultivariate AnalysisVariable*P* ValueHR95% CI*P* ValueRace\<.001\<.001 WhiteReference Black1.5551.416-1.707\<.001 Others[\*](#tf0015){ref-type="table-fn"}1.0400.921-1.175.526Laterality.973 Left RightHistology\<.001\<.001 IDCReference ILC1.0710.930-1.233.342 Others[†](#tf0020){ref-type="table-fn"}0.7410.634-0.866\<.001Grade\<.001\<.001 IReference II1.6481.304-2.083\<.001 III1.9861.574-2.507\<.001Tumor size (cm)\<.001\<.001 ≤2Reference 2-51.3831.267-1.510\<.001 \>51.8571.646-2.095\<.001No. of positive LNs\<.001\<.001 0Reference 1-31.8061.641-1.987\<.001 4-93.1952.859-3.571\<.001 ≥105.3614.725-6.084\<.001ER status\<.001\<.001 PositiveReference Negative1.2211.088-1.370\<.001PR status\<.001.425 PositiveReference Negative1.0460.936-1.170.425Surgery\<.001.004 BCSReference Mastectomy1.1291.040-1.226.004[^5][^6][^7]

Breast Cancer--Specific Survival {#s0055}
--------------------------------

Estimates of probabilities of death resulting from breast cancer and other causes according to clinical characteristics are listed in [Table 3](#t0015){ref-type="table"}. The 5- and 10-year probabilities of death from breast cancer were 11.6% and 20.5%, respectively, while the 5- and 10-year cumulative incidences of death from other causes were 1.1% and 2.6%, respectively. Young black patients exhibited higher cumulative incidence of death than white and "other" patients (*P* \< .001 for all outcomes). There was no significant difference between different lateralities. Tumor grade, tumor size, number of positive lymph nodes, and surgery type were significantly associated with probabilities of death (*P* \< .05 for all outcomes). Infiltrating ductal carcinoma and infiltrating lobular carcinoma, negative ER status, and negative PR status were associated with a significantly higher cumulative incidence of death only among patients who died of breast cancer (*P* \< .001). All variables significantly correlated with cumulative incidences of death resulting from breast cancer were used to construct the nomogram to predict 5- and 10-year BCSS.Table 3Five- and Ten-year Cumulative Incidences of Death Among Patients in the Training CohortTable 3Cumulative Incidence of Death Resulting From Breast CancerCumulative Incidence of Death Resulting From Other CausesVariable5 y10 y*P* Value5 y10 y*P* ValueAll patients0.1160.2050.0110.026Race\<0.001\<0.001 White0.1050.1920.0090.022 Black0.1850.2950.0200.042 Others[\*](#tf0025){ref-type="table-fn"}0.0990.1710.0120.032Laterality0.8810.753 Left0.1150.2020.0110.025 Right0.1180.2080.0100.026Histology\<0.0010.602 IDC0.1200.2080.0110.026 ILC0.1110.2450.0110.030 Others[†](#tf0030){ref-type="table-fn"}0.0870.1410.0130.018Grade\<0.001\<0.001 I0.0150.0510.0090.022 II0.0690.1700.0050.018 III0.1560.2430.0140.031Tumor size (cm)\<0.001\<0.001 ≤20.0590.1230.0090.022 2-50.1480.2560.0100.026 \>50.2690.4010.0270.050No. of positive LNs\<0.001\<0.001 00.0570.1120.0060.017 1-30.1170.2140.0130.028 4-90.2450.3990.0200.039 ≥100.3970.6040.0330.091ER status\<0.0010.085 Positive0.0790.1900.0080.024 Negative0.1810.2320.0150.028PR status\<0.0010.106 Positive0.0790.1860.0090.024 Negative0.1670.2310.0140.028Surgery\<0.0010.009 BCS0.0840.1510.0090.019 Mastectomy0.1420.2510.0120.032[^8][^9]

Construction of the Nomograms {#s0060}
-----------------------------

Nomograms were constructed based on the Cox regression model to predict 5- and 10-year OS and BCSS ([Figure 1](#f0005){ref-type="fig"}). The point assignment of nomograms for OS and BCSS is shown in [Supplementary Table 1](#ec0005){ref-type="supplementary-material"}. Based on the nomograms, tumor grade, tumor size, and number of positive lymph nodes were sharing the largest contribution to prognosis, followed by race and histology. By adding up all points and locating them on the bottom scales, we were easily able to calculate the estimated 5- and 10-year survival probabilities.Figure 1Nomogram for predicting 5- and 10-year probabilities of (A) OS and (B) BCSS of breast cancer in young women. Draw a vertical straight line from the variable value to the axis labeled "Points" to identify points for each variable. Add up all points, and the total points projected on the bottom scales correspond to the 5- and 10-year survival. Abbreviations: *BCS*, breast-conserving surgery; *ER*, estrogen receptor; *IDC*, infiltrating ductal carcinoma; *ILC*, infiltrating lobular carcinoma; *LN*, lymph node.Figure 1

Calibration and Validation of the Nomograms {#s0065}
-------------------------------------------

The calibration plots for the OS and BCSS nomograms in the training cohort ([Supplementary Figure 2](#f0025){ref-type="graphic"}) and validation cohort ([Figure 2](#f0010){ref-type="fig"}) demonstrated an acceptable agreement between the nomogram prediction and observed estimates for 5- and 10-year OS and BCSS. As shown in [Supplementary Table 2](#ec0010){ref-type="supplementary-material"}, in the training cohort, the Harrell\'s C-indexes of the nomograms for the prediction of OS and BCSS were 0.724 \[95% confidence interval (CI), 0.714-0.733\] and 0.733 (95% CI, 0.723-0.743), respectively, which were significantly higher than those of the TNM staging system for OS (0.694; 95% CI, 0.684-0.704; *P* \< .001) and BCSS (0.702; 95% CI, 0.692-0.713; *P* \< .001). The C-indexes for the nomogram were similar in the validation cohort: 0.722 (95% CI, 0.712-0.732) for OS and 0.733 (95% CI, 0.723-0.743) for BCSS. Additionally, C-indexes were significantly greater than those of the TNM staging system at 0.699 (95% CI, 0.689-0.709) and 0.710 (95% CI, 0.700-0.720) for OS and BCSS, respectively.Figure 2Calibration curves for predicting (A) 5-year and (B) 10-year OS and (C) 5-year and (D) 10-year BCSS in the validation cohort. Nomogram-predicted survival is plotted on the *x*-axis, and actual survival is plotted on the *y*-axis. Vertical bars represent 95% CIs measured by Kaplan-Meier analysis. Dashed lines along the 45° line through the origin point represent a perfect calibration model.Figure 2

Performance of the Nomograms in Stratifying Patients According to Risk Scores {#s0070}
-----------------------------------------------------------------------------

We calculated the total points of OS nomogram for every patient in the training cohort and determined the cutoff values by dividing the patients evenly into three subgroups based on total score (0 to 78, 79 to 116, and ≥117). [Supplementary Table 3](#ec0015){ref-type="supplementary-material"} and [Supplementary Figure 3](#f0030){ref-type="graphic"} show that the low-risk subgroup had the best prognosis and the high-risk subgroup had the worst survival. Furthermore, in the validation cohort, patients stratified into different risk subgroups based on cutoff values within each TNM category also exhibited significant differences in survival ([Figure 3](#f0015){ref-type="fig"}).Figure 3Kaplan-Meier curves for overall survival within each TNM stage (A, all patients; B-G, stage I-IIIC) according to risk group stratification in the validation cohort. Subgroups with fewer than 20 patients were omitted from the graphs.Figure 3

Discussion {#s0075}
==========

Breast cancer in young women has several characteristics that differentiate them from breast cancer in other population [@bb0015]. Although several nomograms have been previously reported to predict prognoses in some specific subtypes of breast cancer, no comprehensive nomogram has been developed for young patients with breast cancer [@bb0115], [@bb0120], [@bb0125]. In this study, we developed and validated nomograms to predict 5- and 10-year OS and BCSS for breast cancer in young women. Because the SEER database represents approximately 28% of the US population, the nomograms we developed are highly generalizable and provide personalized estimates of OS and BCSS that can be used by patients and clinicians in making personalized treatment decisions and designing clinical studies.

Although most young women with breast cancer experience breast cancer--associated mortality; some of these patients die from other cancers or noncancer causes. Non--breast cancer-related death might preclude the possibility of death resulting from breast cancer, and censoring those events might lead to biased results [@bb0130], [@bb0135]. Therefore, we introduced a competing-risks model in this study. Competing-risks models have been published in recent years for predicting prognoses in thyroid cancer, breast cancer, prostate cancer, and localized renal cell carcinoma [@bb0115], [@bb0125], [@bb0140], [@bb0145], [@bb0150]. In this study, the 5- and 10-year probabilities of death were 12.7% and 23.1%, respectively. In addition, 5- and 10-year cumulative incidences of death resulting from breast cancer were 11.6% and 20.5%, respectively, indicating a nearly eight-fold higher risk of death from breast cancer than from other causes.

Using log-rank tests, Cox proportional-hazards regression analyses, and competing-risks model, we identified race, histology, tumor grade, tumor size, number of positive lymph nodes, ER status, PR status, and surgery type as independent prognostic factors for both OS and BCSS. These findings were highly concordant with the results of previous studies [@bb0155], [@bb0160], [@bb0165], [@bb0170], [@bb0175]. Previous data have highlighted that young black women have a higher risk of probability of death than young white women [@bb0175], [@bb0180]. Our study confirmed that, after adjustment for other risk factors identified for breast cancer, young white patients have a better OS and BCSS than young black patients. However, there are still some other prognostic markers and molecular profiles that the SEER database did not offer that could be used to predict the survival of breast cancer patients. According to the AJCC 8th edition, HER2 status and multigene panel (such as Oncotype DX) status should also be considered as biology factors that affect the prognosis of breast cancer [@bb0185]. Furthermore, a higher number of young patients with breast cancer carry a pathogenic BRCA1 or BRCA2 mutation compared with patients with onset of breast cancer at an older age [@bb0190], [@bb0195]. The cumulative risk of developing breast cancer is relatively high for BRCA1 or BRCA2 carriers [@bb0200]. Although whether a germline BRCA1 or BRCA2 mutation has independent prognostic implications after an initial cancer diagnosis is unclear, genetic factor should be considered when applying the nomograms.

In addition, adjuvant therapies including chemotherapy and radiotherapy were not selected as candidate factors due to the lack of complete data for treatment history in the SEER database. Thus, it is difficult to accurately distinguish between the categories "no treatment" and "unknown if patients received treatment." Another reason for not selecting treatment as candidate factor is that adjuvant therapies are recommended for patients who have a potentially high risk for disease recurrence or death. Thus, if we include adjuvant therapies into the nomograms, it might result in a certain degree of bias.

In our study, calibration plots showed optimal agreement between predicted and actual probabilities of 5- and 10-year OS and BCSS, thereby demonstrating the reliability of the established nomograms. The C-indexes of our nomograms for OS and BCSS were significantly higher than those for the TNM staging system in both training and validation cohorts, demonstrating good discrimination power. We also separated patients in both cohorts with distinct survival outcomes by stratifying them into three risk groups using total prognostic score. We believe that the identification of subgroups of patients at different risks might have an effect on treatment or care option.

Nevertheless, several limitations should be considered while interpreting our results. First, we excluded a proportion of patients because of missing data for some important variables such as tumor grade, tumor size, and ER and PR status. This might have resulted in some bias in our models. Second, genetic factors and some prognostic parameters including HER2 status, multigene panel status, Ki-67 positivity, body mass index, and smoking status were not recorded in the SEER database between 1990 and 2010, but these factors might improve the robustness and effectiveness of the nomograms [@bb0205], [@bb0210], [@bb0215], [@bb0220], [@bb0225]. Third, the long duration of our study period (1990-2010) may affect the results due to the change of therapeutic strategies, including the establishment of breast-conserving surgery and sentinel lymph node biopsy, improvement of chemotherapy, and application of endocrine therapy and targeted therapy. Although information on radiation therapy and chemotherapy could be accessed from SEER database, they were not recommended for the analysis of survival due to the incompleteness of the variables and biases associated with who receives treatment according to the SEER program. Fourth, young age at diagnosis is a risk factor for recurrence [@bb0230], [@bb0235]. However, the SEER database does not provide information on disease recurrence; thus, we were unable to determine an individualized estimate of the risk of recurrence. Fifth, our models are limited by the retrospective nature of data collection, and thus, these nomograms must be further validated in a prospective cohort before being applied for clinical use.

Conclusion {#s0080}
==========

Using a larger, population-based cohort, we established and validated novel nomograms for predicting the probability of OS and BCSS in young patients with breast cancer. Our developed nomograms perform excellently in both training and validation cohorts. Thus, these nomograms can assist clinicians to precisely estimate the survival of individuals and to identify patients at high risk of death who need more individualized and specialized treatment strategy.

The following are the supplementary data related to this article.Supplementary Table 1Point Assignment of Nomograms for OS and BCSSSupplementary Table 1Supplementary Table 2The Harrell's C-Index for the Nomograms to Predict OS and BCSSSupplementary Table 2Supplementary Table 3Risk Group and Estimated Survival in the Training CohortSupplementary Table 3Supplementary Figure 1Flow diagram for selection of the study cohort.Supplementary Figure 1Supplementary Figure 2Calibration curves for predicting (A) 5-year and (B) 10-year OS and (C) 5-year and (D) 10-year disease-specific survival (BCSS) in the training cohort. Nomogram-predicted survival is plotted on the *x*-axis, and actual survival is plotted on the *y*-axis. Vertical bars represent 95% CIs measured by Kaplan-Meier analysis. Dashed lines along the 45° line through the origin point represent a perfect calibration model.Supplementary Figure 2Supplementary Figure 3Kaplan-Meier curves for overall survival within each TNM stage (A, all patients; B-G, stage I-IIIC) according to risk group stratification in the training cohort. Subgroups with fewer than 20 patients were omitted from the graphs.Supplementary Figure 3
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